Health CanadaGeneral Alert
Clinical trial finds an increased risk of blood clots in the lungs and of death ...
Published: March 15, 2019Recall ID: 59261Category: generalCountry: Canada
Reason for Recall / Hazard
Product safety
Product Description & Identification
Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR)
Additional Source Details
| Field | Value |
|---|---|
| N I D | 59261 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/clinical-trial-finds-increased-risk-blood-clots-lungs-and-death-rheumatoid-arthritis |
| Issue | Product safety |
| Title | Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR) |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2019-03-15 |
| Organization | Communications and Public Affairs Branch |